News - CSL Limited

Filter

Current filters:

CSL Limited

Popular Filters

Report: IPOs and government support can boost the Australian life sciences industry

Report: IPOs and government support can boost the Australian life sciences industry

18-02-2014

Despite a relatively flat December quarter for the PricewaterhouseCoopers Life Sciences Index, it was…

AustraliaBiotechnologyCSL LimitedFinancialMarkets & MarketingPharmaceutical

Australia’s CSL posts solid half-year results

Australia’s CSL posts solid half-year results

13-02-2014

Australian blood products and vaccine maker CSL reported a 3% rise in net profit to $646 million (all…

CSL LimitedFinancialHematologyPharmaceuticalVaccines

Benefits of Kogenate/Helixate NexGen outweigh risks, says EMA unit

Benefits of Kogenate/Helixate NexGen outweigh risks, says EMA unit

08-12-2013

The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) has reviewed the…

BayerCardio-vascularCSL BehringCSL LimitedEuropeHelixateHematologyKogenatePharmaceuticalRegulation

Janssen in-licenses rights to novel cancer therapy from CSL

Janssen in-licenses rights to novel cancer therapy from CSL

05-12-2013

Australian blood products and vaccine maker CSL Ltd has entered into an agreement with Janssen Biotech,…

BiotechnologyCSL LimitedHematologyImmunologicalsJanssen BiotechJohnson & JohnsonLicensingOncology

CSL presents positive data for potential new heart attack therapy

28-11-2013

Australian blood products and vaccine maker CSL says results of a Phase IIa trial of CSL112 in patients…

Cardio-vascularCSL LimitedCSL112PharmaceuticalResearch

CSL settles US antitrust class action litigation

CSL settles US antitrust class action litigation

09-10-2013

Australian blood products and vaccine maker CSL has signed an agreement to settle the US antitrust class…

CSL LimitedFinancialHematologyLegalNorth AmericaPharmaceutical

CSL Behring's rIX-FP shows efficacy in severe hemophilia B

03-07-2013

Data presented by CSL Behring today (July 3) showed clinical efficacy of a once-weekly dosing regimen…

CSL BehringCSL LimitedPharmaceuticalResearch

CSL Behring's Berinert OKed in Europe for short-term prophylaxis in HAE

16-04-2013

Germany-based CSL Behring, a unit of Australia's CSL Ltd (ASX: CSL) says that European health authorities…

BerinertBiotechnologyCSL BehringCSL LimitedEuropeRare diseasesRegulation

CSL Behring gains expanded use for Corifact in USA

06-03-2013

Corifact, Factor XIII Concentrate (Human), to include the peri-operative management of surgical bleeding…

CorifactCSL BehringCSL LimitedNorth AmericaPharmaceuticalRare diseasesRegulation

CSL Behring enrolls first patient in pediatric Ph III pivotal study of rIX-FP to treat hemophilia B

21-01-2013

USA-based CSL Behring, a subsidiary of Australia's CSL Ltd (ASX: CSL) has announced that the first patient…

BiotechnologyCSL BehringCSL LimitedResearchriX-FP

PharmaJet links with Australia's CSL for needle-free flu vaccine delivery

02-12-2012

USA-based PharmaJet has entered into a collaboration with Australia's largest biotech firm CSL Limited…

AfluriaAnti-viralsCSL LimitedHomeNorth AmericaPharmaJetProductionRegulation

Animal models show CSL drug candidate is research breakthrough in diabetes

28-09-2012

Australia's CSL Limited (ASX: CSL) has developed a new drug candidate - dubbed 2H10 - that is able to…

2H10CSL LimitedDiabetesPharmaceuticalResearch

CSL Biotherapies gets US government contract for flu vaccines

11-09-2012

CSL Biotherapies, a US subsidiary of Australia's CSL (ASX: CSL), one of the world's leading manufacturers…

CSL BiotherapiesCSL LimitedFinancialNorth AmericaPharmaceuticalProductionVaccines

CSL Biotherapies indentifies likely reason for Fluvax problems

21-06-2012

Australia's largest biotech firm CSL Biotherapies, a division of CSL Limited (ASX: CSL) today presented…

Asia-PacificBiotechnologyCSL BiotherapiesCSL LimitedFluvaxMarkets & MarketingVaccines

CSL Biotherapies gets official warning letter from US FDA

23-06-2011

The US Food and Drug Administration issued a formal warning letter to Australia’s largest biotech…

AfluriaAsia-PacificBiotechnologyCSL BiotherapiesCSL LimitedNorth AmericaRegulationVaccines

CSL Behring gets European OK for Hizentra

26-04-2011

Germany-based CSL Behring says that the European Commission has granted marketing authorization for Hizentra…

CSL BehringCSL LimitedEuropeHizentraImmunologicalsPharmaceuticalRegulation

Back to top